Sanofi

The European Commission has approved an indication extension in the European Union for our Meningococcal Group A, C, W and Y conjugate vaccine to include use in infants from as young as 6 weeks of age to help protect against invasive meningococcal disease. Read our press release: http://spkl.io/60427z52s

Nenad Tomasevic, Founder and CEO of Dren Bio, joins Alyssa Johnsen, M.D., Ph.D., Senior Vice President, Global Therapeutic Area Head of Immunology and Inflammation Development at Sanofi, to discuss what it takes to drive breakthrough innovation in today's rapidly evolving scientific landscape. Some of the most important advances in medicine happen when diverse expertise comes together. By fostering a culture of curiosity, encouraging teams to challenge conventional thinking and embracing collaboration across disciplines, organizations can create the conditions for innovation to thrive. Watch the full conversation to learn more about how Sanofi and Dren Bio are working together to help shape the future of immunology: http://spkl.io/60407zXI8

12 weeks in. When Belén Garijo returned to Sanofi, she made a commitment: listen first, move fast, and lead with conviction. Watch Belén's full message to hear directly from her about the choices we're making, the science we're advancing, and the future we're building, for patients, for our people, and for the world. Follow Belén Garijo on LinkedIn for more updates. #Sanofi #Leadership #Pharma #Innovation #ChasingTheMiracles

Our Q2 2026 results are now available. Read the full press release for detailed insights: http://spkl.io/60437KQtV #SanofiResults

What if the next breakthrough isn't predicted, but discovered? To develop next-generation medicines, we're building a hypothesis-generating engine. Our Dual Targeting Library (DTL 2.0) screens thousands of molecular pairs in an unbiased way, allowing biological data to reveal unexpected, powerful synergies. It’s a shift from trying to predict the answer to letting science lead the way. 🧬 Discover how, by exploring combinations we might never have imagined, we're uncovering drug synergies that could define the future of medicine—and bring new hope to patients: http://spkl.io/60407KjmO #Neurology #WeNeverSettle

In the latest episode of our Partner Spotlight series, Alyssa Johnsen, M.D., Ph.D., Senior Vice President, Global Therapeutic Area Head of Immunology and Inflammation Development at Sanofi , sits down with Nenad Tomasevic, Founder and CEO of Dren Bio, to discuss how strategic partnerships are helping advance the next generation of treatments for immune mediated diseases. The most impactful collaborations are built on openness, scientific rigor and the agility to let the science lead. By bringing together complementary expertise and a shared commitment to innovation, partnerships can help accelerate promising science with the goal of delivering new therapies for patients. Watch the full conversation to learn more about how Sanofi and Dren Bio are working together to help shape the future of immunology: http://spkl.io/60477Jkwd

Living with CIDP isn't a one-time diagnosis—it's an ongoing journey. And for many people, maintaining function and quality of life remains an ongoing challenge. At Sanofi, we're committed to advancing research on CIDP care, including stability, function, quality of life, and disability reduction. We're investing in research around digital biomarkers and patient-reported outcomes to better understand disease progression in CIDP. Learn more about our commitment to advancing CIDP research: http://spkl.io/60447JunY #CIDP

25 Years of Partnership and Impact 🌍 Since 2001, Sanofi has partnered with the World Health Organization to support efforts against neglected tropical diseases, including human African trypanosomiasis (sleeping sickness), leishmaniasis, and Chagas disease. Together, we're supporting the management of these diseases and expanding access to treatment of sleeping sickness for some of the world's most vulnerable communities. The impact has been remarkable: Reported sleeping sickness cases have fallen by 98% over the past two decades, from more than 25,000 cases per year in 2000 to fewer than 1,000 cases annually since 2018. Today, we celebrate the renewal of this long-standing partnership, building on a shared legacy of scientific innovation, collaboration, and unwavering commitment to improving health equity. The renewed agreement reinforces our support for global efforts toward the elimination of sleeping sickness by 2030 and continued progress against neglected tropical diseases. 💜 👉 Learn more about our partnership: https://lnkd.in/dmGjHN_Q #SocialImpact #GlobalHealth #PublicHealth #HealthEquity #WHO #ChaseTheMiraclesOfScience Photo credit: Brent Stirton/Getty Images for DNDi

Our body is an amazing defender. Every day, it works hard to fight off respiratory viruses, but sometimes, we all need a little extra support to stay healthy and protected. That’s why we’re chasing the miracles of science to explore protection at various stages of life and find solutions across different age groups. We’re committed to helping you and your loved ones in the fight against respiratory viruses. 💜 Discover more: http://spkl.io/60477yxGl #RespiratorySVHealth #ChasingTheMiraclesOfScience #RSV